Role of nitric oxide and platelet-activating factor in cardiac alterations induced by tumor necrosis factor-alpha in the guinea-pig papillary muscle

Cardiovasc Res. 1999 Mar;41(3):611-9. doi: 10.1016/s0008-6363(98)00250-8.

Abstract

Objective: Tumor necrosis factor-alpha (TNF-alpha), a proinflammatory cytokine with negative inotropic properties, is implicated in several pathophysiological events. To clarify the mechanism of action of TNF-alpha on myocardium, we investigated the possible role of platelet-activating factor (PAF) and nitric oxide (NO) as secondary mediators of the depressant effect of this cytokine.

Methods: Isometric twitches and intracellular action potentials were recorded from guinea pig papillary muscles. The effects of TNF-alpha (1-10 ng/ml) were studied in controlled conditions and after treatment with 0.5% Triton X-100, to destroy the endocardial endothelium NG-nitro-L-arginine methyl ester (L-NAME), D-NAME (1 mM) and the two different PAF-receptor antagonists WEB 2170 (3 microM) and CV 3988 (5 microM) were used to study the role of NO and PAF in cardiac depression induced by TNF-alpha. To study the role of NO in cardiac alterations induced by PAF, papillary muscles were pretreated with L-NAME or D-NAME and then challenged with PAF (0.1-1 microM). Nitrite production by papillary muscles challenged with TNF-alpha alone. TNF-alpha in the presence of WEB 2170 or CV 3988, or PAF was studied with the Greiss reagent method. PAF production by papillary muscles stimulated by TNF-alpha was studied by a bioassay method.

Results: TNF-alpha induced an initial, transient positive inotropic effect, then reduced the contractility and the action potential duration in a concentration-dependent manner. Treatment of papillary muscle with Triton X-100 did not modify the response to TNF-alpha, suggesting that the effect of TNF-alpha is not mediated by endocardial endothelial cells. Pretreatment with indomethacin reduced the negative effect of TNF-alpha, while propranolol abolished the initial increase of contractility. The role of PAF and NO as mediators of TNF-alpha was suggested by: (1) the protective effect of L-NAME, but not of D-NAME, on electrical and mechanical alterations; (2) the stimulatory effect of TNF-alpha on nitrite production; (3) the inhibitory effect of WEB 2170 and CV 3988, on both the electromechanical alterations and the nitrite production; (4) the synthesis of PAF induced by TNF-alpha. L-NAME blocked the negative effect of PAF and PAF enhanced nitrite production by papillary muscle.

Conclusions: The present results suggest that in cardiac muscle: (1) the release of PAF triggered by TNF-alpha may account for the stimulation of NO production; (2) both PAF and NO contribute to the development of the electrical and mechanical alterations induced by TNF-alpha; (3) NO production was down-stream to the synthesis of PAF.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Action Potentials / drug effects
  • Adrenergic beta-Antagonists / pharmacology
  • Analysis of Variance
  • Animals
  • Azepines / pharmacology
  • Cyclooxygenase Inhibitors / pharmacology
  • Depression, Chemical
  • Guinea Pigs
  • Heart / drug effects*
  • In Vitro Techniques
  • Indomethacin / pharmacology
  • Myocardial Contraction / drug effects*
  • NG-Nitroarginine Methyl Ester / pharmacology
  • Nitric Oxide / physiology*
  • Nitric Oxide Synthase / antagonists & inhibitors
  • Phospholipid Ethers / pharmacology
  • Platelet Activating Factor / antagonists & inhibitors
  • Platelet Activating Factor / physiology*
  • Platelet Aggregation Inhibitors / pharmacology
  • Propranolol / pharmacology
  • Triazoles / pharmacology
  • Tumor Necrosis Factor-alpha / pharmacology*

Substances

  • Adrenergic beta-Antagonists
  • Azepines
  • Cyclooxygenase Inhibitors
  • Phospholipid Ethers
  • Platelet Activating Factor
  • Platelet Aggregation Inhibitors
  • Triazoles
  • Tumor Necrosis Factor-alpha
  • Nitric Oxide
  • CV 3988
  • Propranolol
  • bepafant
  • Nitric Oxide Synthase
  • NG-Nitroarginine Methyl Ester
  • Indomethacin